Study of the immune state in different variants of anesthetic support for total laryngectomy
DOI:
https://doi.org/10.26641/2307-0404.2023.2.283264Ключевые слова:
anesthetic technique, anesthetic agent, immunosuppression, total laryngectomyАннотация
Peculiarities of operative interventions for malignant neoplasms of the larynx, their traumatic nature, and side effects of opioid use require the search for optimization of anesthesia and perioperative analgesia aimed at reducing surgically and anesthetically induced immunosuppression and related negative consequences.Aim: to investigate the immune status of laryngeal cancer patients with different options of anesthetic support for total laryngectomy and to evaluate the relationship between perioperative immunosuppression and the use of various adjuvant components of analgesia (dexmedetomidine and lidocaine).100 patients with T3-4N0-3M0 laryngeal cancer who underwent total laryngectomy were included in the study. Patients were evenly and comparably divided into 4 research groups (n=25) based on the main clinical and age-sex characteristics (p>0.05) depending on the use of adjuvant components of multimodal anesthesia: in the group 1 they were not used, only opioid analgesics, in group II – lidocaine was used, in group III – dexmedetomidine, and in group IV – both lidocaine and dexmedetomidine. Studies of markers of the immune state (leucoformula, IL-2 and TNF-α) were carried out on the 1st, 2nd, 5th and 7th days after surgery. Statistical analysis was carried out using STATISTICA v.6.1 (Statsoft Inc., USA, license number AGAR909E415822FA), it included parametric and non-parametric, and analytical statistics, parametric and non-parametric variance analysis descriptive of ANOVA, repeated measurements with an assessment of the degree of influence of an independent factor on the studied characteristic. A relatively stable state of cellular immunity and a certain suppression of humoral immunity after total laryngectomy was determined. Immunosuppression was most evident on the 2nd day after surgery in the group 1 with standard opioid anesthesia. The best indicators of the immune state were determined in group IV of the study. The method of anesthesia had the greatest influence on the state of immunosuppression (according to TNF-ɑ) on the 2nd day after surgery – K=30.9% (p<0.001) and was observed within a week after surgery. Lidocaine and dexmedetomidine, as adjuvant components of multimodal anesthesia for total laryngectomy, when used together led to less immunosuppression, contributed to better rates of recovery of the immune status of laryngeal cancer patients compared to the standard approach with the use of opioids.
Библиографические ссылки
Chow LQM. Head and Neck Cancer. N Engl J Med. 2020 Jan 2;382(1):60-72. doi: https://doi.org/10.1056/NEJMra1715715
Hinther A, Nakoneshny SC, Chandarana SP, Matthews TW, Hart R, Schrag C, et al. Efficacy of Multimodal Analgesia for Postoperative Pain Mana-gement in Head and Neck Cancer Patients. Cancers (Basel). 2021 Mar 12;13(6):1266. doi: https://doi.org/10.3390/cancers13061266
Go BC, Go CC, Chorath K, Moreira A, Rajasekaran K. Nonopioid perioperative analgesia in head and neck cancer surgery: A systematic review. World J Otorhinolaryngol Head Neck Surg. 2022 May 9;8(2):107-17. doi: https://doi.org/10.1002/wjo2.62
O'Neill A, Lirk P. Multimodal Analgesia. Anesthesiol Clin. 2022 Sep;40(3):455-68. doi: https://doi.org/10.1016/j.anclin.2022.04.002
Luan T, Li Y, Sun L, Xu S, Wang H, Wang J, Li C. Systemic immune effects of anesthetics and their intracellular targets in tumors. Front Med (Lausanne). 2022 Jul 28;9:810189. doi: https://doi.org/10.3389/fmed.2022.810189
Zhang XY, Liang YX, Yan Y, Dai Z, Chu HC. Morphine: double-faced roles in the regulation of tumor development. Clin Transl Oncol. 2018 Jul;20(7):808-14. doi: https://doi.org/10.1007/s12094-017-1796-x
Kim R. Effects of surgery and anesthetic choice on immunosuppression and cancer recurrence. J Transl Med. 2018 Jan 18;16(1):8.doi: https://doi.org/10.1186/s12967-018-1389-7
Lee IW, Schraag S. The Use of Intravenous Lidocaine in Perioperative Medicine: Anaesthetic, Analgesic and Immune-Modulatory Aspects. J Clin Med. 2022 Jun 20;11(12):3543. doi: https://doi.org/10.3390/jcm11123543
Chalmers A. 22 – Anesthesia and Airway Mana-gement for Oral Cancer and Microvascular Surgery. In: Maxillofacial Surgery. Brennan РА, Schliephake Н, Gha-li GE, Cascarini L, Livingstone C, editors. Third Edition. 2017. p. 355-73.doi: https://doi.org/10.1016/B978-0-7020-6056-4.00023-X
Park E, Cho M, Ki CS. Correct use of repeated measures analysis of variance. Korean J Lab Med. 2009 Feb;29(1):1-9. doi: https://doi.org/10.3343/kjlm.2009.29.1.1
Huang L, Qin C, Wang L, Zhang T, Li J. Effects of dexmedetomidine on immune response in patients undergoing radical and reconstructive surgery for oral cancer. Oncol Lett. 2021 Feb;21(2):106. doi: https://doi.org/10.3892/ol.2020.12367
Mynka NV, Kobeliatskyi JuJu. [The experience of using dexmedetomidine as an adjuvant of anesthesia in ophthalmic surgery]. Medicni perspektivi. 2021;26(1):128-35. Ukrainian.doi: https://doi.org/10.26641/2307-0404.2021.1.227950
Загрузки
Опубликован
Как цитировать
Выпуск
Раздел
Лицензия
Copyright (c) 2023 Medicni perspektivi
![Лицензия Creative Commons](http://i.creativecommons.org/l/by/4.0/88x31.png)
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.